$TCRT News
Last published 1d ago
- 1d agoTCRTSTIFEL 2026 HEALTHCARE CONFERENCE - ALAUNOS THERAPEUTICS INCEarnings Call TranscriptsGood to be here. Appreciate everyone, especially the early morning slot. They're real go-getters. So excited to tell you about Valeris today. There we go. I will be making forward-looking statements. So Valerius was set
- 3w agoTCRTEMEUTES ACT 2 - ALAUNOS THERAPEUTICS INCEarnings Call TranscriptsSubtitles by the Amara.org community Hey Pepe, what are you doing? The demonstration, leave me alone. What have you done with this trash? Why are you still doing this? It's to protest against the studies, the high school
- 1mo agoTCRTAlaunos Therapeutics Announces Acquisition of Velaris TherapeuticsGlobeNewswireAcquisition of Velaris and concurrent oversubscribed $350 million private placement positions the Company to deliver multiple proof-of-concept datasets in pulmonary arterial hypertension Velaris Therapeutics, the ninth
- 1mo agoTCRTParagon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.PR NewswireLeadership team brings proven company-building and drug development experience to Paragon following $10.9 billion acquisition of Apogee by AbbVie Velaris is the ninth company launched around Paragon-discovered assets
- 1mo agoTCRTAlaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rulesGlobeNewswireFORT LAUDERDALE, Fla., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (NASDAQ:TCRT) today announced that it has entered into definitive agreements with institutional investors in a registered direct
- 4mo agoTCRTAlaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse StudyGlobeNewswireThis statistical finding supports a lower liver-weight signal after adjustment for body fat percentage, suggesting the finding was not fully explained by measured body fat in this modelLiver-weight findings are
- 5mo agoTCRTAlaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse StudiesGlobeNewswireALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and improved liver
- 5mo agoTCRTAlaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity ModelsGlobeNewswireFORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (NASDAQ:TCRT) today announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evaluating ALN1003, the
- 6mo agoVBIOTCRTValion Bio Appoints Melinda Lackey as General CounselPR NewswireValion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a clinical-stage immunotherapeutics company developing Entolimod™ for Acute...
- 8mo agoTCRTAlaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic DisordersGlobeNewswireThe lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse modelALN1003 also demonstrated reductions in liver weight and improvements in select
- 1y agoELABTCRTPMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto StrategiesGlobeNewswireNEWPORT BEACH, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC ("PMGC Capital"), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB), today issued a public statement urging Alaunos Therapeutics,
- 1y agoELABTCRTPMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)GlobeNewswireNEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC ("PMGC Capital," "we," "our," or "us"), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB), today announced its planned filing of a
- 2y agoTCRTAlaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic AlternativesGlobeNewswireTCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patientshunTR® discovered
- 3y agoTCRTAlaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic AlternativesGlobeNewswireTCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patientsCompany to wind down
- 3y agoTCRTAlaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic MalignanciesGlobeNewswireHOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics
- 3y agoTCRTAlaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual MeetingGlobeNewswireTCR-T cell therapy shows first-in-human response for non-viral TCR-T therapy; effectively targets high frequency TP53 and KRAS driver mutations across multiple solid tumor indicationsTreatment was well tolerated with a
- 3y agoTCRTAlaunos Therapeutics, Inc. (TCRT) Q1 2023 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoTCRTAlaunos Therapeutics Reports First Quarter 2023 Financial ResultsGlobeNewswireActively enrolling patients and manufacturing cryopreserved products for TCR-T Library Phase 1/2 trial; expect to report interim data in the third quarter of 2023Fully prepaid loan with Silicon Valley Bank; now a
- 3y agoTCRTAlaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023GlobeNewswireHOUSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics
- 3y agoTCRTAlaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual MeetingGlobeNewswireHOUSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of
- 3y agoTCRTAlaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of DirectorsGlobeNewswireHOUSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of
- 3y agoTCRTAlaunos Therapeutics to Participate in Upcoming Investor Conferences in AprilGlobeNewswireHOUSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of
- 3y agoTCRTAlaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewswireGenerated cutting-edge translational data demonstrating safety, persistence and functionality of infused TCR-T cells in the tumor microenvironment; provides support for next generation TCR-T effortsAdvancing TCR-T
- 3y agoTCRTAlaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023GlobeNewswireHOUSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it will report financial
- 3y agoTCRTAlaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023GlobeNewswireAnnouncing addition of two new TCRs to the library, estimated to double the addressable market; plans to further expand TCR library using hunTR® TCR discovery platformIncreasing patient enrollment to advance TCR-T
- 3y agoTCRTAlaunos Therapeutics Announces Pricing of Public Offering of Common StockGlobeNewswireHOUSTON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a clinical-stage oncology-focused cell therapy company, today announced the pricing of its underwritten
- 3y agoTCRTAlaunos Therapeutics Announces Proposed Public Offering of Common StockGlobeNewswireHOUSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it has commenced an
- 3y agoTCRTAlaunos Therapeutics Reports Third Quarter 2022 Financial ResultsGlobeNewswirePresented early data highlighting first successful objective clinical response using non-viral Sleeping Beauty TCR-T cell therapy in solid tumors at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference
- 4y agoTCRTAlaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022GlobeNewswireHOUSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), today announced that it will report financial results for the third quarter ended September 30, 2022 on
- 4y agoTCRTAlaunos Therapeutics to Present Data Highlighting its hunTR™ TCR Discovery Platform at the Society for Immunotherapy of Cancer 2022 Annual MeetingGlobeNewswireData supports high-throughput screening process to identify neoantigen-reactive TCRsExclusive ownership of discovered KRAS mutation-reactive TCRshunTR enables expansion of the Company's hotspot mutation targeted TCR
- 4y agoTCRTAlaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy ConferenceGlobeNewswireFirst patient achieved a confirmed partial response with 51.2% tumor regression with TCR-T cell persistence ongoing at 3 months post infusion Sleeping Beauty TCR-T cell therapy had a manageable safety profile with no dose limiting toxicities observed
- 4y agoTCRTAlaunos Therapeutics to Participate in Upcoming Investor Conferences in SeptemberGlobeNewswireHOUSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a clinical-stage oncology-focused cell therapy company, today announced Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.
- 4y agoTCRTAlaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using its TCR-T Cell TherapyGlobeNewswireFirst patient dosed achieved a confirmed objective partial response Second patient dosed at second dose level; cleared 28-day safety window Data to be presented on Friday, September 30 at 8:30am ET in a proffered presentation at the CRI-ENCI-AACR
- 4y agoTCRTAlaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy ConferenceGlobeNewswireHOUSTON, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it has been accepted to present a proffered talk at the CRI-E
- 4y agoTCRTAlaunos Therapeutics Reports Second Quarter 2022 Financial ResultsGlobeNewswireAdvancing TCR-T Library Phase 1/2 trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications; plan to present early data in 3Q 2022 at a scientific conference; moving ahead with second dose level Extended Cooperative Research and
- 4y agoTCRTAlaunos Therapeutics to Report Second Quarter 2022 Financial Results on August 15, 2022GlobeNewswireHOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), today announced that it will report financial results for the second quarter ended June 30, 2022 on Monday, August 15, 2022, before the op
- 4y agoTCRTAlaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical OperationsGlobeNewswireHOUSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a clinical-stage oncology-focused cell therapy company, today announced the appointment of Abhishek Srivastava, Ph.D. as Vice President of
- 4y agoTCRTCellChorus Announces Scientific Advisory BoardBusiness WireIndustry experts Rebecca Berdeaux, PhD, Dimitrios Kontoyiannis, MD, PhD, and Laurence Cooper, MD, PhD to advise on CellChorus growth initiatives CellChorus Inc., the leader in applying artificial intelligence to visually evaluate how cells perform an
- 4y agoTCRTAlaunos Therapeutics to Present at the Jefferies Healthcare ConferenceGlobeNewswireHOUSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a clinical-stage oncology-focused cell therapy company today announced that Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger,
- 4y agoTCRTAlaunos Therapeutics to Present Trials in Progress Poster for its TCR-T Library Phase 1/2 trial at the 2022 American Society of Clinical Oncology Annual MeetingGlobeNewswireHOUSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a clinical-stage oncology-focused cell therapy company today announced a Trials in Progress poster presentation at the 2022 American Societ
- 4y agoTCRTAlaunos Therapeutics Reports First Quarter 2022 Financial ResultsGlobeNewswireSuccessfully dosed first patient in TCR-T Library Phase 1/2 trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications Will present preclinical data today at the ASGCT 25th Annual Meeting highlighting the potential of mbIL-15 as
- 4y agoTCRTAlaunos Therapeutics to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewswireHOUSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a clinical-stage oncology-focused cell therapy company today announced that Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, P
- 4y agoTCRTAlaunos Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022GlobeNewswireHOUSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), today announced that it will report financial results for the first quarter ended March 31, 2022 on Monday, May 16, 2022, before the open o
- 4y agoTCRTAlaunos Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual MeetingGlobeNewswirePreclinical data to be presented highlights the potential ability to generate mbIL-15 TCR-T cells targeting hotspot mutations expressed in solid tumors with enhanced survival capacity HOUSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics,
- 4y agoTCRTAlaunos Therapeutics Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid TumorsGlobeNewswireFirst-in-human non-viral TCR-T cell therapy targeting shared hotspot mutations in solid cancers First clinical product manufactured and administered to a patient using the Company's in house cGMP manufacturing facility Expect to report initial data in
- 4y agoTCRTZIOPCARsgen Appoints Dr. Raffaele Baffa as Chief Medical OfficerPR NewswireSHANGHAI and BOSTON, April 7, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Raffa
- 4y agoTCRTAlaunos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewswirePhase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications; first patient consented and is expected to dose in 2Q 2022 Extended CRADA with the National Cancer Institute focused on evaluating Alaunos' TCR-T
- 4y agoTCRTAlaunos Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 30, 2022GlobeNewswireHOUSTON, March 16, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), today announced that it will report financial results for the fourth quarter ended December 31, 2021 on Wednesday, March 30, 2022, before
- 4y agoTCRTAlaunos Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare ConferenceGlobeNewswireHOUSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a clinical-stage oncology-focused cell therapy company, today announced that the Company's Chief Executive Officer, Kevin S. Boyle Sr., a